

Hilton Virginia Beach Oceanfront Virginia Beach, Virginia





Sentara Vascular Specialists


2022 MID-ATLANTIC CONFERENCE

10th ANNUAL CURRENT CONCEPTS IN

#### **VASCULAR THERAPIES**



#### Vertebrobasilar Insufficiency





Justin Milligan MD Sentara Vascular Specialists

# Vertebrobasilar Insufficiency (VBI)


- VBI, coined in the 1950's after C. Miller Fisher used 'carotid insufficiency" to describe TIA in the carotid supplied territories
  - VBI therefore often used to describe brief episodes of transient ischemic attacks in the vertebrobasilar territory.
- Posterior circulation → brainstem, thalamus, hippocampus, cerebellum, occipital and medial temporal lobes.
- Presentation shares features with several other more common etiologies including labyrinthitis, vestibular neuritis, and benign paroxysmal positional vertigo.


## **Anatomy**





## **Anatomy**





1st major branch:
Posterior Inferior
Cerebellar Artery
(PICA)

2<sup>nd</sup> major branch: **Anterior spinal Artery** 

Then merges to form **Basilar artery** 


# Vertebrobasilar Insufficiency (VBI)

- As with other types of strokes, infarct can occur from either an **embolism**, **in-situ thrombosis**, or lacunar disease secondary to chronic hypertension.
- Usually, VBI is caused by 2 processes of ischemia:
  - Hemodynamic insufficiency
  - Embolism
    - Unlike the carotid arteries, embolism via the vertebral arteries is not common.
    - Donor sites for embolism may include the aortic arch, the origin of the vertebral artery or the proximal subclavian arteries. Most cases, however, are due to atherosclerotic disease.

# Vertebrobasilar Insufficiency (VBI)

- <u>Hemodynamic insufficiency</u> → causes most VBI.
  - Inadequate blood flow through the basilar artery, especially in the elderly and diabetic populations with poor sympathetic control.
  - Symptoms tend to be reproducible and short, rarely causing infarction
  - Must be an incomplete contribution via carotid circulation via the posterior communicating artery in the circle of Willis.
- Other causes for a decrease in perfusion → antihypertensive medications, cardiac arrhythmia, pacemaker malfunction, and vasculitis.
- Occlusions in other blood vessels (i.e Subclavian Steal syndrome) may also cause VBI by "stealing" blood flow from the brainstem as blood flows down the path of least resistance

## **Subclavian Steal**



#### Lancet (1986)

- 500 patients with asymptomatic neck bruits were followed prospectively for up to 4 years
- 9% of patients (45/500) had severe subclavian stenosis
  - 64% (32/45) positive subclavian-steal test
    - Left-sided lesions (27/32).
  - <u>No patients</u> had symptoms as a result of arm exercise during the steal test, and no patients had stroke during follow-up.
  - Reversed flow down one vertebral artery is relatively common in patients and is usually asymptomatic

## SYMPTOMS OF VBI



- Vertigo (the most common symptom)
- Dizziness/syncope (60% of VBI)
- "Drop attacks:"
- Diplopia/Loss of vision
- Dysphagia/dysarthria
- Headache
- Ataxia
- Loss of temperature and pain
- Incontinence

### PHYSICAL EXAM OF VBI


- Alteration in pupil size and reactivity (CNIII)
- Horizontal gaze palsy (CN VI lesion)
- Facial nerve (CN VII) paralysis
- Bulbar palsy (CN IX, XI, XII) w/ dysarthria, dysphonia, dysphagia, dysarthria, facial weakness
- Contralateral hemianopsia with macular sparing (posterior cerebral artery involvement)
- Ipsilateral temperature loss and facial pain (CN V)


## **VERTIGO**

- Benign conditions that may also cause similar symptoms such as labyrinthitis, vestibular neuritis, and most commonly benign paroxysmal positional vertigo.
- Vertigo is a common symptom in VBI.
- Vertigo in the presence of brainstem signs or symptoms will be diagnostic of vertebrobasilar territory TIA.
- Look for brainstem signs or cranial nerve abnormalities


#### **Subclavian-Carotid Transposition**

#### **SCA Revascularization**





Carotid – Subclavian Bypass



### **Cervical Bypass**

SERIES	N	MORTALITY	STROKE	MI	SURVIVAL (5Y)	SURVIVAL (10Y)	PATENCY (5Y)	PATENCY (10Y)
Crawford (1983)	99	1	2	NA	NA	NA	NA	NA
Salam (1993)	31	0	0	0	NA	NA	NA	NA
Salam (1994)	41	0	0	0	NA	NA	73	NA
Berguer (1999)	182	0.5	3.8	3	72	41	91	82
Byrne (2007)	143	0.7	1.4	4.3	NA	NA	92	NA

## SCA Revascularization ENDO VS OPEN

- Primary patency rates (1, 3, and 5 yr)
  - Endo: 93%, 78%, and 70%
  - Open: 100%, 98%, and 96%
- Major complication rate: 5.8% vs. 5.9%
- Stroke <1% in endovascular series</li>
- Cumulative endo 5-yr patency: 77-89%.

#### **Vertebral Revascularization**

- V1: carotid-vertebral transposition.
   Also bypass and endarterectomy.
  - 1% stroke / death
  - RLN palsy, Horner's syndrome, chylothorax
  - 5-yr patency 95%
- V2: not easily accessible –
  proximal/distal ligation +/- bypass
  if symptoms.

- V3: saphenous bypass
  - 4% stroke /death
  - 8% immediate graft thrombosis
  - 5-yr patency: 87%
- Vertebral angioplasty +/- stent
  - 6.4% stroke / death
  - No long-term data

#### Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT

- Symptomatic vertebral stenosis of at least 50% resulting from presumed atheromatous disease.
- Participants were randomly assigned (1 : 1) to either vertebral angioplasty/stenting plus BMT (n = 91) or BMT alone (n = 88). A total of 182 patients were initially enrolled
- The primary end point was the occurrence of fatal or non-fatal stroke in any arterial territory during follow-up.
- Median follow-up was 3.5 years
  - 61 patients who were stented
    - 48 (78.7%) had extracranial stenosis
    - 13 (21.3%) had intracranial stenosis.

Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT

- The primary end point was the occurrence of fatal or non-fatal stroke in any arterial territory during follow-up.
  - No perioperative complications w/ extracranial stenting; 2 CVA w/ intracranial stenting.
  - 5 /91 (including one fatal stroke) in the stent group
  - 12/88 patients (including two fatal strokes) in the medical group
  - Hazard ratio of 0.40, 95% confidence interval 0.14 to 1.13; p = 0.08)
  - Absolute risk reduction of 25 strokes per 1000 person-years.
- The study was underpowered because it failed to reach target recruitment.
- Conclusions: The trial found no significant difference in risk of the primary end point between the two
  groups.


2022 MID-ATLANTIC CONFERENCE

10th ANNUAL CURRENT CONCEPTS IN

#### **VASCULAR THERAPIES**



### Thank You!



Justin Milligan MD Sentara Vascular Specialists